Articles by tag: bladder-cancer

FDA approved Imfinzi: first immunotherapeutic combination for bladder cancer

FDA approved Imfinzi (durvalumab) + BCG for high-risk non-muscle-invasive bladder cancer. 32% reduction in recurrence risk. Learn about the breakthrough in oncourology.

FDA approval of combination immunotherapy for bladder cancer: durvalumab + BCG

FDA approved durvalumab with BCG for high-risk NMIBC. POTOMAC data: 32% risk reduction. Analysis of efficacy, toxicity, and consequences of BCG shortage. Learn more.

AI diagnosis of bladder cancer: 99% accuracy and Vesta breakthrough

AI increases accuracy of bladder cancer diagnosis to 99%. Analysis of the VisioCyt vs Vesta battle: who received FDA breakthrough status and why it changes urology. Read.

AI test for bladder cancer: FDA breakthrough device

FDA has granted breakthrough device designation to an AI tool for predicting bladder cancer prognosis. Learn how Vesta by Valar Labs is changing oncourology and treatment economics.